Evidence map›Paper›PMID 33777023›Full record

ArticleFrontiers in immunology2021

A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection.

Julia Makinde, Eunice W Nduati, Anna Freni-Sterrantino, Claire Streatfield, Catherine Kibirige, Jama Dalel, S Lucas Black, Peter Hayes, Gladys Macharia, Jonathan Hare and 9 more

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Julia MakindeIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Eunice W NduatiKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Anna Freni-SterrantinoDepartment of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom.
Claire StreatfieldIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Catherine KibirigeIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Jama DalelIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
S Lucas BlackIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Peter HayesIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Gladys MachariaIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Jonathan HareIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Edward McGowanIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Brian AbelIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Deborah KingIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Sarah JosephIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
IAVI Protocol C Investigators
Eric HunterEmory Vaccine Centre, Yerkes National Primate Research Centre, Emory University, Atlanta, GA, United States.
Eduard J SandersKenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
Matt PriceIAVI, New York, NY, United States.
Jill GilmourIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
NIH HHS P51 OD011132
6 · The paper itself

Abstract

Individuals infected with HIV display varying rates of viral control and disease progression, with a small percentage of individuals being able to spontaneously control infection in the absence of treatment. In attempting to define the correlates associated with natural protection against HIV, extreme heterogeneity in the datasets generated from systems methodologies can be further complicated by the inherent variability encountered at the population, individual, cellular and molecular levels. Furthermore, such studies have been limited by the paucity of well-characterised samples and linked epidemiological data, including duration of infection and clinical outcomes. To address this, we selected 10 volunteers who rapidly and persistently controlled HIV, and 10 volunteers each, from two control groups who failed to control (based on set point viral loads) from an acute and early HIV prospective cohort from East and Southern Africa. A propensity score matching approach was applied to control for the influence of five factors (age, risk group, virus subtype, gender, and country) known to influence disease progression on causal observations. Fifty-two plasma proteins were assessed at two timepoints in the 1st year of infection. We independently confirmed factors known to influence disease progression such as the B

Indexed as

Virus ReplicationAdaptor Proteins, Signal TransducingAdultAfricaBiomarkersDisease ProgressionFemaleHIV-1HIV InfectionsHLA-B AntigensHumansIncidenceInterleukin-17MaleRetrospective StudiesRisk AssessmentAdaptor Proteins, Signal TransducingBiomarkersHLA-B57 antigenHLA-B AntigensIL17C protein, humanInterleukin-17MAPKAP1 protein, humanelite controllersHIV-1immunology & infectious diseasesinfection–immunologyviral control

Identifiers

PMID33777023
PMCPMC7991997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.